Kim Nichols, MD, Director of the Division of Cancer Predisposition at St. Jude Children’s Research Hospital, invites you to participate in a study of Thrombocytopenia 5, a leukemia predisposition syndrome associated with pathogenic germline ETV6 variants. Further research is needed to better understand how ETV6 variants influence disease manifestations, delivery of leukemia therapy, development of short and long-term toxicities, and overall and event-free survival. To this end, the ETV6 Registry will gather de-identified information on individuals with germline ETV6 variants worldwide to address these clinically relevant but as yet poorly understood domains.

If you are interested in learning more about this study, please reach out to Dr. Nichols at Kim.nichols@stjude.org.  Thank you in advance for considering participation in this important study.